Exact Sciences (EXAS) Stock Forecast & Price Target

$61.66 -0.03 (-0.05%)

(As of 01:03 PM ET)

Exact Sciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 19 Analyst Ratings

Sell
0

Hold
1

Buy
18

Based on 19 Wall Street analysts who have issued ratings for Exact Sciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 1 has given a hold rating, and 18 have given a buy rating for EXAS.

Consensus Price Target

$75.29
22.11% Upside

According to the 19 analysts' twelve-month price targets for Exact Sciences, the average price target is $75.29. The highest price target for EXAS is $95.00, while the lowest price target for EXAS is $60.00. The average price target represents a forecasted upside of 22.11% from the current price of $61.66.

Get the Latest News and Ratings for EXAS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Exact Sciences and its competitors.

EXAS Analyst Ratings Over Time

Type	Current Forecast 12/4/23 to 12/3/24	1 Month Ago 11/4/23 to 11/3/24	3 Months Ago 9/5/23 to 9/4/24	1 Year Ago 12/4/22 to 12/4/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	18 Buy rating(s)	15 Buy rating(s)	15 Buy rating(s)	12 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$75.29	$80.64	$78.50	$96.56
Forecasted Upside	22.11% Upside	15.53% Upside	37.41% Upside	47.06% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Moderate Buy

This company will win the AI race (Ad)

Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

EXAS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EXAS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Exact Sciences Stock vs. The Competition

Type	Exact Sciences	Medical Companies	S&P 500
Consensus Rating Score	2.95	2.81	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	23.21% Upside	25,916.81% Upside	7.05% Upside
News Sentiment Rating	Positive News See Recent EXAS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/26/2024	TD Cowen 5 of 5 stars		Boost Target	Buy ➝ Buy	$82.00 ➝ $86.00	+45.05%
11/26/2024	BTIG Research 2 of 5 stars		Boost Target	Buy ➝ Buy	$65.00 ➝ $75.00	+25.94%
11/21/2024	William Blair 2 of 5 stars		Reiterated Rating	Outperform
11/11/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$85.00 ➝ $75.00	+45.69%
11/6/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$84.00 ➝ $85.00	+56.14%
11/6/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$80.00 ➝ $75.00	+37.77%
This company will win the AI race (Ad) Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry.
11/6/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$95.00 ➝ $75.00	+39.61%
11/6/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$82.00 ➝ $67.00	+24.72%
11/6/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	V. Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$80.00 ➝ $60.00	+15.65%
11/6/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$75.00 ➝ $65.00	+25.29%
11/6/2024	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Jackson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$67.00 ➝ $65.00	-9.10%
11/6/2024	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$82.00 ➝ $65.00	-9.10%
11/6/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$70.00 ➝ $67.00	-6.31%
10/30/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$75.00 ➝ $90.00	+26.26%
9/26/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform
8/27/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Couillard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$75.00	+25.23%
6/27/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Nam Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$70.00	+58.51%
12/14/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$90.00	+32.92%
12/13/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$95.00	+44.99%
8/2/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$105.00 ➝ $110.00	+14.06%
8/2/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$75.00 ➝ $90.00	-6.68%
5/5/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$73.00	+10.96%
2/22/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$56.00 ➝ $76.00	+24.06%
1/12/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$70.00 ➝ $75.00	+9.59%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:30 PM ET.

EXAS Forecast - Frequently Asked Questions

: According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Exact Sciences is $75.29, with a high forecast of $95.00 and a low forecast of $60.00.
: 19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There is currently 1 hold rating and 18 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EXAS shares.
: According to analysts, Exact Sciences's stock has a predicted upside of 22.11% based on their 12-month stock forecasts.
: Exact Sciences has been rated by research analysts at Benchmark, BTIG Research, Canaccord Genuity Group, Citigroup, Craig Hallum, Evercore ISI, Jefferies Financial Group, Piper Sandler, Raymond James, Robert W. Baird, Sanford C. Bernstein, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, and William Blair in the past 90 days.
: Analysts like Exact Sciences more than other "medical" companies. The consensus rating score for Exact Sciences is 2.95 while the average consensus rating score for "medical" companies is 2.81. Learn more on how EXAS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Musk’s new company could top a trillion? (Ad)

The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.

Click here to see the details because there’s not much time to prepare.

This page (NASDAQ:EXAS) was last updated on 12/3/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exact Sciences (EXAS) Stock Forecast & Price Target